1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Cellectis S.A.
  6. News
  7. Summary
    ALCLS   FR0010425595

CELLECTIS S.A.

(ALCLS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

European ADRs Move Lower in Friday Trading

01/21/2022 | 11:11am EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
AKARI THERAPEUTICS, PLC 3.40% 1.1271 Delayed Quote.-24.86%
ARCELORMITTAL 1.00% 27.4 Real-time Quote.-2.65%
AVADEL PHARMACEUTICALS PLC -5.19% 3.84 Delayed Quote.-52.48%
BHP GROUP LIMITED 2.05% 47.18 Delayed Quote.13.69%
BIOFRONTERA AG 0.00% 1.06 Delayed Quote.-28.38%
BIONTECH SE -2.90% 163 Delayed Quote.-36.77%
BRITISH AMERICAN TOBACCO PLC 0.15% 3437.5 Delayed Quote.25.50%
CELLECTIS S.A. -2.26% 3.54 Real-time Quote.-52.42%
EDAP TMS S.A. -3.49% 7.18 Delayed Quote.19.87%
MEREO BIOPHARMA GROUP PLC 8.76% 0.5329 Delayed Quote.-66.69%
NATUZZI S.P.A. -3.55% 9.78 Delayed Quote.-36.35%
NUCANA PLC 0.00% 0.6 Delayed Quote.-74.79%
TRINITY BIOTECH PLC 3.28% 1.26 Delayed Quote.-11.89%
UNILEVER PLC 1.88% 3516.5 Delayed Quote.-10.87%
VIA OPTRONICS AG -2.14% 2.75 Delayed Quote.-62.59%
All news about CELLECTIS S.A.
05/20CALYXT, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Stand..
AQ
05/20European ADRs Move Sharply Higher in Friday Trading
MT
05/19European ADRs Move Higher in Thursday Trading
MT
05/18Baird Upgrades Cellectis to Outperform From Neutral
MT
05/17European ADRs Move Higher in Tuesday Trading
MT
05/16Cellectis Presents Research Data on a Novel Immune-Evasive Universal CAR T-cell at ASGC..
GL
05/16Cellectis Presents Research Data on a Novel Immune-Evasive Universal CAR T-cell at ASGC..
AQ
05/16Cellectis Presents Research Data on A Novel Immune-Evasive Universal CAR T-Cell At ASGC..
CI
05/13Barclays Lowers Cellectis S.A's Price Target to $7 From $9, Overweight Rating Maintaine..
MT
05/13TRANSCRIPT : Cellectis S.A., Q1 2022 Earnings Call, May 13, 2022
CI
More news
Analyst Recommendations on CELLECTIS S.A.
More recommendations
Financials
Sales 2022 66,7 M 70,3 M 70,3 M
Net income 2022 -83,5 M -88,1 M -88,1 M
Net cash 2022 42,6 M 44,9 M 44,9 M
P/E ratio 2022 -1,60x
Yield 2022 -
Capitalization 161 M 170 M 170 M
EV / Sales 2022 1,78x
EV / Sales 2023 -1,27x
Nbr of Employees 297
Free-Float 84,3%
Chart CELLECTIS S.A.
Duration : Period :
Cellectis S.A. Technical Analysis Chart | ALCLS | FR0010425595 | MarketScreener
Technical analysis trends CELLECTIS S.A.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 3,54 €
Average target price 16,00 €
Spread / Average Target 352%
EPS Revisions
Managers and Directors
André Choulika Chief Executive Officer & Director
Bing C. Wang Chief Financial Officer
Jean-Pierre Garnier Non-Executive Chairman
Philippe Duchateau Chief Scientific Officer
Carrie Brownstein Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
CELLECTIS S.A.-52.42%170
MODERNA, INC.-46.35%54 195
LONZA GROUP AG-27.84%41 796
IQVIA HOLDINGS INC.-28.46%38 202
SEAGEN INC.-9.68%25 704
ICON PUBLIC LIMITED COMPANY-30.22%17 567